Researchers have found that drugs similar to Ozempic, a popular weight‑loss medication, appear to dampen not only appetite but also the urge for alcohol and other addictive substances. The discovery points to the lateral septum, a small brain area previously overlooked, as a possible „craving center.” The findings come from a series of animal studies and early human observations conducted across several universities in 2025‑2026.
Initial trials showed that mice given semaglutide, the active ingredient in Ozregic, ate less and also chose fewer alcohol‑laden solutions when presented with alternatives. Follow‑up experiments revealed that the drug reduced activity in the lateral septum, a region linked to reward processing and stress responses. „We were surprised to see such a clear drop in alcohol‑seeking behavior,” said Dr. Lina Patel, a neuroscientist at the University of Cambridge. The effect persisted even after the animals’ weight normalized, suggesting the drug’s influence extends beyond simple caloric restriction.
The lateral septum sits deep within the brain’s limbic system, connecting the hippocampus with the hypothalamus. Historically, scientists focused on the nucleus accumbens and ventral tegmental area when studying addiction. However, recent imaging studies in humans taking GLP‑1 receptor agonists— the drug class that includes Ozempic—showed reduced blood‑flow signals in the lateral septum during exposure to alcohol cues. „This region seems to act as a gatekeeper for reward‑related impulses,” explained Dr. Patel. In rodent models, chemically silencing the lateral septum mimicked the appetite‑suppressing effects of Ozempic, while stimulating it restored normal drinking patterns. The data suggest that GLP‑1 drugs may recalibrate the brain’s reward circuitry, making cravings less compelling.
The prospect of repurposing weight‑loss medicines for addiction treatment is gaining traction. Clinical trials in the United Kingdom and the United States are now enrolling participants with alcohol use disorder to test whether weekly semaglutide injections can curb drinking frequency. Early results are promising: participants reported a 30 % reduction in heavy‑drinking days after three months, without major side effects. Critics caution that long‑term safety remains unknown, especially for individuals without obesity. Nevertheless, the potential public‑health impact is significant, as current pharmacotherapies for alcohol dependence have limited efficacy. If GLP‑1 agonists prove effective, they could offer a dual‑benefit approach—addressing both obesity and substance abuse.
The discovery of the lateral septum’s role reshapes our understanding of how the brain regulates desire. It opens avenues for new drugs that target this region more precisely, possibly with fewer metabolic effects. As research progresses, clinicians may soon have a powerful tool to help patients break free from both overeating and addictive habits.
How does Ozempic affect cravings for substances other than food? Ozempic activates GLP‑1 receptors, which in turn dampen activity in the lateral septum, a brain area that amplifies reward signals. This reduces the perceived pull of alcohol and potentially other drugs.
Is it safe to use Ozempic for treating alcohol dependence? Current studies suggest short‑term safety, but long‑term effects in non‑obese patients are still under investigation. Doctors will weigh benefits against risks before prescribing it off‑label.
Will targeting the lateral septum replace existing addiction treatments? Not immediately. The lateral septum offers a new therapeutic target, but it will likely complement, rather than replace, established medications and behavioral interventions.